# A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine

> **NCT06291857** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Novavax** · enrollment: 9320 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant
- **BIOLOGICAL:** Novavax COVID-19 Vaccine
- **BIOLOGICAL:** tNIV Vaccine
- **BIOLOGICAL:** Fluzone High Dose

## Key facts

- **NCT ID:** NCT06291857
- **Lead sponsor:** Novavax
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-12-09
- **Primary completion:** 2026-07-26
- **Final completion:** 2026-09-30
- **Target enrollment:** 9320 (ACTUAL)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06291857

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06291857, "A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06291857. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*